Ubiquitin proteasome system as a pharmacological target in neurodegeneration

References

• Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron40(2), 427–446 (2003).
   PubMed Web of Science ®Google Scholar
• Alves-Rodrigues A, Gregori L, Figueiredo-Pereira ME. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci.21(12), 516–520 (1998).
   PubMed Web of Science ®Google Scholar
• Scheper W, Hol EM. Protein quality control in Alzheimer’s disease: a fatal saviour. Curr. Drug Targets. CNS. Neurol. Disord.4(3), 283–292 (2005).
   PubMedGoogle Scholar
• Ross CA, Poirier MA. Opinion: what is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell Biol.6(11), 891–898 (2005).
   PubMed Web of Science ®Google Scholar
• Varshavsky A. Regulated protein degradation. Trends Biochem. Sci.30(6), 283–286 (2005).
   PubMed Web of Science ®Google Scholar
• Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature426(6968), 895–899 (2003).
   PubMed Web of Science ®Google Scholar
• Hol EM, van Leeuwen FW, Fischer DF. The proteasome in Alzheimer’s disease and Parkinson’s disease: lessons from ubiquitin B+1. Trends Mol. Med.11(11), 488–495 (2005).
   PubMed Web of Science ®Google Scholar
• de Vrij FM, Fischer DF, van Leeuwen FW, Hol EM. Protein quality control in Alzheimer’s disease by the ubiquitin proteasome system. Prog. Neurobiol.74(5), 249–270 (2004).
   PubMed Web of Science ®Google Scholar
• Pickart CM, Eddins MJ. Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta1695(1–3), 55–72 (2004).
   PubMed Web of Science ®Google Scholar
• Gao M, Karin M. Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. Mol. Cell19(5), 581–593 (2005).
   PubMed Web of Science ®Google Scholar
• Pickart CM, Fushman D. Polyubiquitin chains: polymeric protein signals. Curr. Opin. Chem. Biol.8(6), 610–616 (2004).
   PubMed Web of Science ®Google Scholar
• Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J.19(1), 94–102 (2000).
   PubMed Web of Science ®Google Scholar
• Pickart CM, Cohen RE. Proteasomes and their kin: proteases in the machine age. Nat. Rev. Mol. Cell Biol.5(3), 177–187 (2004).
   PubMed Web of Science ®Google Scholar
• Navon A, Goldberg AL. Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome. Mol. Cell8(6), 1339–1349 (2001).
   PubMed Web of Science ®Google Scholar
• Hartmann-Petersen R, Seeger M, Gordon C. Transferring substrates to the 26S proteasome. Trends Biochem. Sci.28(1), 26–31 (2003).
   PubMed Web of Science ®Google Scholar
• Lam YA, Lawson TG, Velayutham M, Zweier JL, Pickart CM. A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature416(6882), 763–767 (2002).
   PubMed Web of Science ®Google Scholar
• Hu M, Li P, Song L et al. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J.24(21), 3747–3756 (2005).
   PubMed Web of Science ®Google Scholar
• Stone M, Hartmann-Petersen R, Seeger M, Bech-Otschir D, Wallace M, Gordon C. Uch2/Uch37 is the major deubiquitinating enzyme associated with the 26S proteasome in fission yeast. J. Mol. Biol.344(3), 697–706 (2004).
   PubMed Web of Science ®Google Scholar
• Nijman SM, Luna-Vargas MP, Velds A et al. A genomic and functional inventory of deubiquitinating enzymes. Cell123(5), 773–786 (2005).
   PubMed Web of Science ®Google Scholar
• Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim. Biophys. Acta1695(1–3), 189–207 (2004).
   PubMed Web of Science ®Google Scholar
• Schlieker C, Korbel GA, Kattenhorn LM, Ploegh HL. A deubiquitinating activity is conserved in the large tegument protein of the herpesviridae. J. Virol.79(24), 15582–15585 (2005).
   PubMed Web of Science ®Google Scholar
• Ratia K, Saikatendu KS, Santarsiero BD et al. Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc. Natl Acad. Sci. USA103(15), 5717–5722 (2006).
   PubMed Web of Science ®Google Scholar
• Richter-Landsberg C, Goldbaum O. Stress proteins in neural cells: functional roles in health and disease. Cell Mol. Life Sci.60(2), 337–349 (2003).
   PubMed Web of Science ®Google Scholar
• Lee S, Tsai FT. Molecular chaperones in protein quality control. J. Biochem. Mol. Biol.38(3), 259–265 (2005).
   PubMedGoogle Scholar
• Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat. Cell Biol.7(8), 766–772 (2005).
   PubMed Web of Science ®Google Scholar
• Yoneda T, Urano F, Ron D. Transmission of proteotoxicity across cellular compartments. Genes Dev.16(11), 1307–1313 (2002).
   PubMed Web of Science ®Google Scholar
• Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol.143(7), 1883–1898 (1998).
   PubMed Web of Science ®Google Scholar
• Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol.10(12), 524–530 (2000).
   PubMed Web of Science ®Google Scholar
• Reggiori F, Klionsky DJ. Autophagosomes: biogenesis from scratch? Curr. Opin. Cell Biol.17(4), 415–422 (2005).
   PubMed Web of Science ®Google Scholar
• Levine B, Yuan J. Autophagy in cell death: an innocent convict? J. Clin. Invest.115(10), 2679–2688 (2005).
   PubMed Web of Science ®Google Scholar
• Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem.280(48), 40282–40292 (2005).
   PubMed Web of Science ®Google Scholar
• Iwata A, Christianson JC, Bucci M et al. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc. Natl Acad. Sci. USA102(37), 13135–13140 (2005).
   PubMed Web of Science ®Google Scholar
• Hara T, Nakamura K, Matsui M et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature441(7095), 885–889 (2006).
   PubMed Web of Science ®Google Scholar
• Komatsu M, Waguri S, Chiba T et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature441(7095), 880–884 (2006).
   PubMed Web of Science ®Google Scholar
• Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol.14(1), 20–28 (2004).
   PubMed Web of Science ®Google Scholar
• Kopito RR. Biosynthesis and degradation of CFTR. Physiol. Rev.79(1 Suppl.), S167–S173 (1999).
   PubMed Web of Science ®Google Scholar
• Egan ME, Glockner-Pagel J, Ambrose C et al J. Calcium-pump inhibitors induce functional surface expression of δ F508-CFTR protein in cystic fibrosis epithelial cells. Nat. Med.8(5), 485–492 (2002).
   PubMed Web of Science ®Google Scholar
• Mall M, Kunzelmann K. Correction of the CF defect by curcumin: hypes and disappointments. Bioessays27(1), 9–13 (2005).
   PubMed Web of Science ®Google Scholar
• Powell K, Zeitlin PL. Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting. Adv. Drug Deliv. Rev.54(11), 1395–1408 (2002).
   PubMed Web of Science ®Google Scholar
• Assereto S, Stringara S, Sotgia F et al. Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment. Am. J. Physiol. Cell Physiol.290(2), C577–C582 (2006).
   Google Scholar
• Bonifati V, Oostra BA, Heutink P. Unraveling the pathogenesis of Parkinson’s disease-the contribution of monogenic forms. Cell Mol. Life Sci.61(14), 1729–1750 (2004).
   PubMed Web of Science ®Google Scholar
• Ding Q, Dimayuga E, Keller JN. Proteasome regulation of oxidative stress in aging and age-related diseases of the CNS. Antioxid. Redox. Signal.8(1–2), 163–172 (2006).
   PubMed Web of Science ®Google Scholar
• Chondrogianni N, Gonos ES. Proteasome dysfunction in mammalian aging: steps and factors involved. Exp. Gerontol.40(12), 931–938 (2005).
   PubMed Web of Science ®Google Scholar
• Farout L, Friguet B. Proteasome function in aging and oxidative stress: implications in protein maintenance failure. Antioxid. Redox. Signal.8(1–2), 205–216 (2006).
   PubMed Web of Science ®Google Scholar
• Ciechanover A. The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology66(2 Suppl. 1), S7–S19 (2006).
   PubMed Web of Science ®Google Scholar
• Cripps D, Thomas S, Jeng Y, Yang F, Davies P, Yang A. Alzheimer’s-disease-specific conformation of hyperphosphorylated phf-tau Is polyubiquitinated through lys-48, lys-11, and lys-6 ubiquitin conjugation. J. Biol. Chem.281(16), 10825–10838 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang M, Windheim M, Roe SM et al. Chaperoned ubiquitylation-crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex. Mol. Cell20(4), 525–538 (2005).
   PubMed Web of Science ®Google Scholar
• Petrucelli L, Dickson D, Kehoe K et al. CHIP and Hsp70 regulate Tau ubiquitination, degradation and aggregation. Hum. Mol. Genet.13(7), 703–714 (2004).
   PubMed Web of Science ®Google Scholar
• Shang F, Deng G, Liu Q et al. Lys6-modified ubiquitin inhibits ubiquitin-dependent protein degradation. J. Biol. Chem.280(21), 20365–20374 (2005).
   PubMed Web of Science ®Google Scholar
• Fischer DF, de Vos RA, van Dijk R et al. Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. FASEB J.17(14), 2014–2024 (2003).
   PubMed Web of Science ®Google Scholar
• van Leeuwen FW, van Tijn P, Sonnemans MA et al. Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies. Neurology66(2 Suppl. 1), S86–S92 (2006).
   Web of Science ®Google Scholar
• van Leeuwen FW, de Kleijn DP, van den Hurk HH et al. Frameshift mutants of β amyloid precursor protein and ubiquitin-B in Alzheimer’s and down patients. Science279(5348), 242–247 (1998).
   PubMed Web of Science ®Google Scholar
• de Vrij FM, Sluijs JA, Gregori L et al. Mutant ubiquitin expressed in Alzheimer’s disease causes neuronal death. FASEB J.15(14), 2680–2688 (2001).
   PubMed Web of Science ®Google Scholar
• Ding Q, Markesbery WR, Chen Q, Li F, Keller JN. Ribosome dysfunction is an early event in Alzheimer’s disease. J. Neurosci.25(40), 9171–9175 (2005).
   PubMed Web of Science ®Google Scholar
• Ding Q, Dimayuga E, Markesbery WR, Keller JN. Proteasome inhibition induces reversible impairments in protein synthesis. FASEB J.20(8), 1055–1063 (2006).
   PubMed Web of Science ®Google Scholar
• McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson’s disease. Exp. Neurol.179(1), 38–46 (2003).
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Vigouroux S, Wong H et al. Brain proteasomal function in sporadic Parkinson’s disease and related disorders. Ann. Neurol.51(6), 779–782 (2002).
   PubMed Web of Science ®Google Scholar
• McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci. Lett.326(3), 155–158 (2002).
   PubMed Web of Science ®Google Scholar
• Blandini F, Sinforiani E, Pacchetti C et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology66(4), 529–534 (2006).
   PubMed Web of Science ®Google Scholar
• de Pril R, Fischer DF, Maat-Schieman ML et al. Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum. Mol. Genet.13(16), 1803–1813 (2004).
   PubMed Web of Science ®Google Scholar
• Burnett B, Li F, Pittman RN. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum. Mol. Genet.12(23), 3195–3205 (2003).
   PubMed Web of Science ®Google Scholar
• Kalchman MA, Graham RK, Xia G et al. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J. Biol. Chem.271(32), 19385–19394 (1996).
   PubMed Web of Science ®Google Scholar
• Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington’s disease mice: exclusion of proteasome activator REGγ as a therapeutic target. Hum. Mol. Genet.15(1), 33–44 (2006).
   PubMed Web of Science ®Google Scholar
• Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol. Cell14(1), 95–104 (2004).
   PubMed Web of Science ®Google Scholar
• Groll M, Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim. Biophys. Acta1695(1–3), 33–44 (2004).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control10(5), 361–369 (2003).
   PubMedGoogle Scholar
• Richardson PG, Barlogie B, Berenson J et al. A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med.348(26), 2609–2617 (2003).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J et al. Extended follow-up of a Phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer106(6), 1316–1319 (2006).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med.352(24), 2487–2498 (2005).
   PubMed Web of Science ®Google Scholar
• Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol.15(1), 27–33 (2005).
   PubMed Web of Science ®Google Scholar
• Verma R, Peters NR, D’Onofrio M et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science306(5693), 117–120 (2004).
   PubMed Web of Science ®Google Scholar
• Miller VM, Nelson RF, Gouvion CM et al. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J. Neurosci.25(40), 9152–9161 (2005).
   PubMed Web of Science ®Google Scholar
• Chen Q, Thorpe J, Dohmen JR, Li F, Keller JN. Ump1 extends yeast lifespan and enhances viability during oxidative stress: central role for the proteasome? Free Radic. Biol. Med.40(1), 120–126 (2006).
   PubMed Web of Science ®Google Scholar
• Chondrogianni N, Tzavelas C, Pemberton AJ, Nezis IP, Rivett AJ, Gonos ES. Overexpression of proteasome β5 assembled subunit increases the amount of proteasome and confers ameliorated response to oxidative stress and higher survival rates. J. Biol. Chem.280(12), 11840–11850 (2005).
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shichinohe H, Kuroda S, Ishikawa T, Iwasaki Y. Neuroprotective effect of a heat shock protein inducer, geranylgeranylacetone in permanent focal cerebral ischemia. Brain Res.1032(1–2), 176–182 (2005).
   PubMed Web of Science ®Google Scholar
• Katsuno M, Sang C, Adachi H et al. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc. Natl Acad. Sci. USA102(46), 16801–16806 (2005).
   PubMed Web of Science ®Google Scholar
• Waza M, Adachi H, Katsuno M et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med.11(10), 1088–1095 (2005).
   PubMed Web of Science ®Google Scholar
• Berkers CR, Verdoes M, Lichtman E et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat. Methods2(5), 357–362 (2005).
   PubMed Web of Science ®Google Scholar
• Ishiura S, Sano M, Kamakura K, Sugita H. Isolation of two forms of the high-molecular-mass serine protease, ingensin, from porcine skeletal muscle. FEBS Lett.189(1), 119–123 (1985).
   PubMed Web of Science ®Google Scholar
• Lam YA, Huang JW, Showole O. The synthesis and proteasomal degradation of a model substrate Ub5DHFR. Methods Enzymol.398, 379–390 (2005).
   PubMed Web of Science ®Google Scholar
• Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat. Biotechnol.18(5), 538–543 (2000).
   PubMed Web of Science ®Google Scholar
• Fiebiger E, Story C, Ploegh HL, Tortorella D. Visualization of the ER-to-cytosol dislocation reaction of a type I membrane protein. EMBO J.21(5), 1041–1053 (2002).
   PubMed Web of Science ®Google Scholar
• Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science292(5521), 1552–1555 (2001).
   PubMed Web of Science ®Google Scholar
• Chauhan D, Catley L, Li G et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell8(5), 407–419 (2005).
   PubMed Web of Science ®Google Scholar
• Dang LC, Melandri FD, Stein RL. Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes. Biochemistry37(7), 1868–1879 (1998).
   PubMed Web of Science ®Google Scholar
• Wada H, Kito K, Caskey LS, Yeh ET, Kamitani T. Cleavage of the C-terminus of NEDD8 by UCH-L3. Biochem. Biophys. Res. Commun.251(3), 688–692 (1998).
   PubMed Web of Science ®Google Scholar
• Hemelaar J, Borodovsky A, Kessler BM et al. Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol. Cell Biol.24(1), 84–95 (2004).
   PubMed Web of Science ®Google Scholar
• Hemelaar J, Galardy PJ, Borodovsky A, Kessler BM, Ploegh HL, Ovaa H. Chemistry-based functional proteomics: mechanism-based activity-profiling tools for ubiquitin and ubiquitin-like specific proteases. J. Proteome Res.3(2), 268–276 (2004).
   PubMed Web of Science ®Google Scholar
• Borodovsky A, Ovaa H, Kolli N et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol.9(10), 1149–1159 (2002).
   PubMedGoogle Scholar
• Evans PC, Ovaa H, Hamon M et al. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem. J.378(Pt 3), 727–734 (2004).
   PubMed Web of Science ®Google Scholar
• Blum G, Mullins SR, Keren K et al. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat. Chem. Biol.1(4), 203–209 (2005).
   PubMed Web of Science ®Google Scholar
• Atlas. Country resources for neurological disorders. WHO Press (2004).
   Google Scholar
• Victor MD, Ropper AH.Adams & Victor’s Principles of Neurology (8th Edition). McGraw-Hill, NY, USA (2005).
   Google Scholar
• Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J.14(1), 65–77 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang X, Smith DL, Meriin AB et al. A potent small molecule inhibits polyglutamine aggregation in Huntington’s disease neurons and suppresses neurodegeneration in vivo. Proc. Natl Acad. Sci. USA102(3), 892–897 (2005).
   PubMed Web of Science ®Google Scholar
• Arts GJ, Langemeijer E, Tissingh R et al. Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res.13(10), 2325–2332 (2003).
   PubMed Web of Science ®Google Scholar
• van Es HH, Arts GJ. Biology calls the targets: combining RNAi and disease biology. Drug Discov. Today10(20), 1385–1391 (2005).
   PubMed Web of Science ®Google Scholar
• Wong PC, Cai H, Borchelt DR, Price DL. Genetically engineered mouse models of neurodegenerative diseases. Nat. Neurosci.5(7), 633–639 (2002).
   PubMed Web of Science ®Google Scholar
• Mott RT, Dickson DW, Trojanowski JQ et al. Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J. Neuropathol. Exp. Neurol.64(5), 420–428 (2005).
   PubMed Web of Science ®Google Scholar
• Paviour DC, Lees AJ, Josephs KA et al. Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes: broadening the clinical picture to include progressive supranuclear palsy. Brain127(Pt 11), 2441–2451 (2004).
   PubMed Web of Science ®Google Scholar
• Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson’s disease. Annu. Rev. Neurosci.28, 57–87 (2005).
   PubMed Web of Science ®Google Scholar
• Uchikado H, Delledonne A, Uitti R, Dickson DW. Coexistence of PSP and MSA: a case report and review of the literature. Acta Neuropathol. (Berl.)111(2), 186–192 (2006).
   PubMed Web of Science ®Google Scholar
• Rubinsztein DC. Lessons from animal models of Huntington’s disease. Trends Genet.18(4), 202–209 (2002).
   PubMed Web of Science ®Google Scholar
• Tomokane N, Iwaki T, Tateishi J, Iwaki A, Goldman JE. Rosenthal fibers share epitopes with αB-crystallin, glial fibrillary acidic protein, and ubiquitin, but not with vimentin. Immunoelectron microscopy with colloidal gold. Am. J. Pathol.138(4), 875–885 (1991).
   PubMed Web of Science ®Google Scholar
• Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J. Neuropathol. Exp. Neurol.64(8), 649–664 (2005).
   PubMed Web of Science ®Google Scholar